At a time of frequent population movements throughout the world, there is a fear that new infectious diseases spreads instantaneously across countries. It is difficult for conventional vaccines and treatments to cope with the successive emergence and spread of new infections, and a technological platform utilizing the latest technologies and findings in bioengineering and virology is needed to rapidly develop vaccines and drugs. πBIO is such a technological platform and is expected to produce vaccine seeds and treatments fast enough to prevent large-scale viral epidemics in their early stages. πBIO brings together the latest knowledge and technologies in protein engineering, bioinformatics, and immunology. The name πBIO is derived from Protein Immuno-engineering Biologics. The core technology of πBIO is the Solubility Controlling Peptide tag technology that controls (usually increases) the immune response against of viral protein and thus helps produce neutralizing antibodies. πBIO targets the epidemic viruses, their variants, or seasonal variant viruses. πBIO is a versatile technological platform that can be used against a large variety of viruses. It is key to establish ongoing partnerships with vaccine development companies, drug discovery development companies, and open laboratories of major pharmaceutical companies.
